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ABSTRACT
Introduction: To evaluate the efficacy and
safety of onabotulinumtoxinA for the
treatment of neurogenic detrusor overactivity
(NDO) in subpopulations of etiology (multiple
sclerosis [MS] or spinal cord injury [SCI]) and
concomitant anticholinergics (use/non-use).
Methods: Data were pooled from two double-
blind, placebo-controlled, pivotal, phase 3
studies including a total of 691 patients with
C14 urinary incontinence (UI) episodes/week
due to MS (n = 381) or SCI (n = 310). Patients
received intradetrusor injections of
onabotulinumtoxinA 200U (n = 227), 300U
(n = 223), or placebo (n = 241). Change from
baseline at week 6 in UI episodes/week (primary
endpoint), urodynamics, quality of life (QOL),
and adverse events (AEs) were assessed.
ClinicalTrials.gov identifiers: NCT00311376 and
NCT00461292.
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Results: Significant and similar reductions in
UI episodes were observed regardless of etiology
or anticholinergic use: at week 6, mean weekly
decreases of -22.6 and -19.6 were seen in MS
and SCI patients, respectively, and -20.3 and
-22.5 in anticholinergic users and non-users,
respectively, treated with onabotulinumtoxinA
200U. The 300U dose did not add to the clinical
efficacy in any subpopulation. Similar
proportions of patients achieved C50% or
100% reductions in UI episodes in all
subgroups. Improvements in maximum
cystometric capacity, maximum detrusor
pressure during first involuntary detrusor
contraction, and QOL were significant in both
etiologies and were independent of
anticholinergic use. The most common AEs in
all groups were urinary tract infection and
urinary retention.
Conclusion: Regardless of concomitant
anticholinergic use or etiology,
onabotulinumtoxinA significantly improved
UI symptoms, urodynamics, and QOL in
patients with UI due to NDO.
OnabotulinumtoxinA was well tolerated in all
groups.
Keywords: Botulinum toxin; Multiple sclerosis;
OnabotulinumtoxinA; Spinal cord injury;
Urinary incontinence
INTRODUCTION
Patients with neurologic conditions such as
multiple sclerosis (MS) or spinal cord injury
(SCI) often have neurogenic detrusor
overactivity (NDO), which frequently results in
urinary incontinence (UI) and high detrusor
pressures [1, 2]. OnabotulinumtoxinA
(BOTOX, Allergan, Inc., Irvine, CA, USA) has
been shown to be effective in the treatment of
UI due to neurogenic detrusor overactivity in
MS and SCI patients in phase 2 trials [3–5] and
in two double-blind, placebo-controlled, phase
3 registration trials [6, 7]. The phase 3 trials
demonstrated significant reductions in UI as
well as improvements in urodynamic
parameters and quality of life (QOL) with
onabotulinumtoxinA in patients who had
been inadequately managed with
anticholinergic medications. Where approved,
the 200U dose of onabotulinumtoxinA is the
registered dose for the treatment of patients
with UI due to NDO. Units of biological activity
of onabotulinumtoxinA cannot be compared
with or converted into units of any other
botulinum toxin product, and
onabotulinumtoxinA is not interchangeable
with other botulinum toxin preparations.
In this analysis, we further evaluated the
efficacy and safety of onabotulinumtoxinA in
the patients with the two neurologic etiologies
(MS and SCI) separately. In addition, there were
differences in regard to the use of
anticholinergics. The study protocols required
all patients to have been inadequately managed
with at least one anticholinergic for their UI.
Some patients chose to continue using
concomitant anticholinergics during the phase
3 studies, while others discontinued their
anticholinergics prior to study start and
remained off them throughout the study. The
trial population thus consisted of two distinct
subpopulations of patients: those taking
onabotulinumtoxinA plus a concomitant
anticholinergic medication, and those who
received onabotulinumtoxinA alone.
Therefore, we also examined the impact of
concomitant anticholinergic use/non-use on
the efficacy and safety of
onabotulinumtoxinA. Pooling the data from
these trials provided a larger sample size to
examine the effect of onabotulinumtoxinA
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Details regarding study design and patient
selection for these studies have been described
previously [6, 7]. Briefly, the pivotal phase
3 trials (DIGNITY studies; ClinicalTrials.
gov NCT00311376 and NCT00461292) were
international, multicenter, randomized,
double-blind, placebo-controlled trials
conducted in accordance with the ethical
standards of the responsible committee on
human experimentation (institutional and
national) and with the Helsinki Declaration of
1975, as revised in 2000, and all study
participants provided written informed
consent. The studies included patients with
C14 UI episodes per week due to NDO
from SCI or MS. Study protocols required all
patients to have been inadequately managed
with at least one anticholinergic for their UI,
defined as an inadequate response or intolerable
side effects after [1 month on an optimized
dose. The protocol design allowed patients to
remain on anticholinergic medication to
provide more protection to the upper urinary
tract for those randomized to the placebo group
in treatment cycle 1. Those taking
anticholinergics had to maintain them at the
baseline dose throughout the study, and those
not taking anticholinergics were to remain off
them. Patients were either using clean
intermittent catheterization (CIC) prior to
study entry or had to be willing to initiate CIC
if necessary.
Patients were randomized 1:1:1 to receive 30
1-mL intradetrusor injections of placebo,
onabotulinumtoxinA 200U, or 300U,
administered cystoscopically, avoiding the
trigone. Patients were followed for 52 weeks
and evaluated post treatment at weeks 2, 6, and
12, and every 6 weeks thereafter. A second
treatment could be requested from 12 weeks
after treatment 1 onward.
Efficacy and Safety Assessments
Change from baseline in weekly UI episodes, as
well as the proportion of patients achieving
C50% or 100% (complete dryness) reduction
from baseline in UI episodes, was evaluated in
all subgroups. Changes from baseline in
maximum cystometric capacity (MCC),
maximum detrusor pressure during first
involuntary detrusor contraction (PdetmaxIDC),
and percentage of patients with no involuntary
detrusor contraction (IDC) were assessed.
Health-related QOL was evaluated using the
change from baseline in the Incontinence
Quality of Life (I-QOL) questionnaire total
summary score [8]. Other assessments included
the time to patient request for retreatment
(measuring duration of effect) and a general
satisfaction with treatment question (5-point
rating scale from very satisfied to very
dissatisfied).
Adverse events (AEs) were recorded
throughout the study. No distinction was
made between asymptomatic and
symptomatic urinary tract infections (UTIs) in
these studies. The recording of urinary
retention as an AE was based on the
investigator’s clinical judgment.
Statistical Analysis
Analysis of covariance was used to assess
efficacy in the intent-to-treat (ITT; all
randomized patients) population, with
baseline value as a covariate, and treatment
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arm and investigative site as factors. The
placebo-controlled comparison focused on the
first 12 weeks after treatment 1, before patients
were eligible for retreatment. In MS patients
who were not using CIC at baseline, patient
satisfaction with treatment at week 6 was
compared between those who initiated CIC
and those who remained off CIC post
treatment using the Cochran–Mantel–Haenszel
test, controlling for treatment group. Patients
who responded with ‘‘very satisfied’’ or
‘‘somewhat satisfied’’ to the general satisfaction
with treatment question were categorized as
‘‘satisfied’’ in the analysis, whereas patients who
responded with ‘‘neutral,’’ ‘‘somewhat
dissatisfied,’’ or ‘‘very dissatisfied’’ were
categorized as ‘‘dissatisfied.’’ Median time to
patient request for retreatment was evaluated
using Kaplan–Meier analysis, and 95%
confidence intervals (CI) were calculated.
The safety population consisted of all
randomized patients treated on day 1 and who
received study drug (analyzed according to dose
actually received).
RESULTS
Efficacy and Safety by Etiology
The pooled ITT population from both studies
combined (N = 691) included 381 patients with
MS and 310 with SCI. Most baseline
characteristics were comparable between the
groups (Table 1). Differences included gender
(the majority of SCI patients were male; the
majority of MS patients were female), baseline
CIC use (SCI 84.8%, MS 29.4%), baseline
anticholinergic use (SCI 60.0%, MS 50.7%),
and baseline values for PdetmaxIDC (SCI
58.1 ± 40.4, MS 39.7 ± 29.8; Table 2).
Both MS and SCI patients exhibited
consistently significant decreases from baseline
in UI episodes following onabotulinumtoxinA
treatment compared with placebo at week 6,
with mean weekly decreases of -14.0, -22.6,
and -24.0 in MS patients (P\0.05) and -6.4,
-19.6, and -18.2 in SCI patients (P\0.001) in
the placebo, onabotulinumtoxinA 200U, and
300U groups, respectively (Fig. 1a). A
significantly higher proportion of MS and SCI
patients (P\0.001 for both) treated with
onabotulinumtoxinA achieved C50% or 100%
reduction (i.e., dry) in weekly UI episodes at
week 6 compared with the placebo group
(Fig. 1b). At week 6, dry rates were 10.7%,
41.5%, and 44.2% in MS patients and 7.3%,
30.9%, and 35.9% in SCI patients in the placebo,
onabotulinumtoxinA 200U, and 300U groups,
respectively. No clinically relevant difference in
reduction of UI episodes was observed between
the dose groups in either etiology.
The change in the number of voluntary
voids per week was examined in the non-
catheterizing MS subpopulation. In contrast to
SCI patients (13.5% voiding voluntarily at
baseline), the majority of MS patients were not
using CIC at baseline and were voiding
spontaneously (69.6%). At week 6 following
onabotulinumtoxinA treatment, the number of
voluntary voids per week significantly decreased
in MS patients who were not catheterizing at
baseline compared with placebo (P B 0.05 for
both doses; Fig. 2). The number of voluntary
voids per week was not assessed in the SCI
subpopulation because there were too few SCI
patients who were not catheterizing at baseline
to allow for a meaningful analysis.
Both MS and SCI patients treated with
onabotulinumtoxinA showed significantly
greater increases in MCC from baseline at
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week 6 compared with placebo (P\0.001 for
all; Table 2). The magnitude of increase was
similar between the etiologies and between the
onabotulinumtoxinA dose groups. A large
proportion of onabotulinumtoxinA-treated
patients in both etiologies had no IDC (up to
a filled volume of 500 mL) at week 6 relative to
placebo (18.5%, 68.0%, and 70.9% [P\0.001]
in MS patients and 18.2%, 58.7%, and 57.6%
[P\0.001] in SCI patients in the placebo,
onabotulinumtoxinA 200U, and 300U groups,
respectively; Table 2). In patients who had an
IDC, decreases from baseline in PdetmaxIDC were
significantly greater compared with placebo at
week 6 (P\0.001 for MS patients, P\0.05 for
SCI patients). SCI patients showed decreases of
-42.7 and -35.3 in the respective
onabotulinumtoxinA 200U and 300U groups,
compared with decreases of -22.1 and -24.1 in
MS patients (Table 2).
Both MS and SCI patients demonstrated
significant improvements compared with
placebo in I-QOL total summary score. The
magnitude of change from baseline for both
etiologies and both onabotulinumtoxinA doses
was considerably greater than 11 points, which
is the established minimally important
difference (MID) [8] (Fig. 3).
In the MS population, the median time to
patient request for retreatment was 295 and
307 days in the onabotulinumtoxinA 200U and
300U groups, respectively, whereas the SCI
population requested retreatment earlier at
253 and 211 days in the onabotulinumtoxinA
200U and 300U groups, respectively. The
median time to patient request for retreatment
in the placebo group was 92 days for both
etiologies, which is close to the minimum
permissible time of 12 weeks after initial
treatment (P\0.001 for both doses vs placebo).
Adverse events across treatment cycle 1 for
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Table 3. UTI was the most common AE in both
etiologies. The incidence of UTIs was similar
among all treatment groups for SCI patients
(P = 0.534), but was higher in the
onabotulinumtoxinA-treated MS patients
compared with placebo (P\0.001). Very few
complicated UTIs were reported: pyelonephritis
was reported in one MS patient
(onabotulinumtoxinA 300U group) and in two
SCI patients (both in the placebo group), and
urosepsis was reported in two SCI patients (both
in the placebo group).
The AE of urinary retention was further
examined only in MS patients as most SCI
patients were already performing CIC at study
entry. Urinary retention appeared to show a
dose-dependent increase in those MS patients
who were not catheterizing at baseline. The rate
Fig. 1 a Mean change from baseline in weekly UI
episodes; b responder rates for C50% and 100% reductions
in UI episodes at week 6 in the MS and SCI
subpopulations. *P\0.001; P\0.05 vs placebo. MS
multiple sclerosis, OnabotA onabotulinumtoxinA, SCI
spinal cord injury, UI urinary incontinence
Fig. 2 Mean change from baseline in voluntary voids per
week in MS patients who were not using CIC at baseline.
*P\0.001; P\0.05 vs placebo. CIC clean intermittent
catheterization, MS multiple sclerosis, OnabotA
onabotulinumtoxinA
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of de novo CIC due to urinary retention during
treatment cycle 1 was 31.4% (27/86) and 47.1%
(41/87) in the onabotulinumtoxinA 200U and
300U groups, respectively, compared with 4.5%
(4/88) in the placebo group. The duration of de
novo CIC for urinary retention in MS patients
treated with onabotulinumtoxinA 200U (the
approved dose where licensed) is illustrated in
Fig. 4: 15.1% of patients used de novo CIC for
B36 weeks, while 16.3% used CIC for
[36 weeks. Importantly, 68.6% of the MS
patients who received onabotulinumtoxinA
200U did not initiate CIC during treatment
cycle 1.
The proportion of MS patients who initiated
CIC for any reason in treatment cycle 1 was
17%, 40%, and 51% in the placebo,
onabotulinumtoxinA 200U, and 300U groups,
respectively. In these patients, the mean weekly
frequency of CIC was not significantly different
among groups; 13.4, 18.1, and 21.1 (P = 0.417)
at week 6 after treatment and 9.4, 16.8, and 17.2
(P = 0.365) at week 12 in the placebo,
onabotulinumtoxinA 200U, and 300U groups,
respectively. The impact of initiation of CIC on
patient satisfaction with treatment was assessed
in MS patients (Fig. 5). Satisfaction (defined as
‘‘very satisfied’’ or ‘‘somewhat satisfied’’) with
onabotulinumtoxinA treatment remained high
regardless of CIC initiation, with no statistically
significant difference in satisfaction between
the groups initiating CIC and those who did not
for the 200U dose group (P = 0.167); however, a
significant difference was observed for the 300U
dose group (P = 0.048).
Efficacy and Safety by Baseline
Anticholinergic Use
At the time of study entry, the majority of the
patients had previously tried one (59.2%) or two
(21.0%) different anticholinergics (Table 4).
Most patients (76.1%) were inadequately
managed with anticholinergics due to
inadequate efficacy. In the pooled ITT
population, 379/691 (55%) of patients were
taking anticholinergics at baseline.
Significant reductions in weekly UI episodes
were observed with onabotulinumtoxinA 200U
and 300U within the anticholinergic user and
non-user subgroups (P B 0.05 vs placebo for
both subgroups; Fig. 6a). Comparison in UI at
week 6 between the two subgroups did not yield
statistically significant (P = 0.454) or clinically
Fig. 3 Mean change from baseline at week 6 in the I-QOL
total score by etiology. Dashed line indicates the MID of an
11-point increase from baseline [8]. *P\0.001 vs placebo.
I-QOL Incontinence Quality of Life, MID minimally
important difference, MS multiple sclerosis, OnabotA
onabotulinumtoxinA, SCI spinal cord injury
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relevant differences. Likewise, similar
proportions of patients within the
anticholinergic user and non-user subgroups
achieved C50% or 100% reductions in weekly
UI episodes at week 6 (Fig. 6b). Dry rates for
placebo, onabotulinumtoxinA 200U, and 300U
were 7.9%, 36.7%, and 39.5% in the
anticholinergic user and 10.9%, 37.4%, and
41.3% in the non-user subgroups, respectively
(P\0.001 vs placebo each for users and non-
users).
Significant and similar increases in MCC in
the onabotulinumtoxinA groups compared
with placebo were seen in both anticholinergic
users and non-users (Table 2). Decreases in
PdetmaxIDC and increases in I-QOL total
summary scores were also similar regardless of
anticholinergic use. Mean increases from
baseline in I-QOL total summary scores at
week 6 were 11.4, 28.7, and 31.9 for users
(P = 0.001 vs placebo) and 10.8, 22.7, and 26.3
for non-users of anticholinergics (P B 0.002 vs
placebo) in the placebo, onabotulinumtoxinA
200U, and 300U groups, respectively. The
median times to patient request for
retreatment were 99 (95% CI, 92–127), 269
(95% CI, 211–310), and 296 (95% CI,
253–420) days in anticholinergic users
compared with 88 (95% CI, 88–103), 266 (95%
CI, 221–337), and 253 (95% CI, 209–295) days
in non-users in the placebo,
onabotulinumtoxinA 200U, and 300U groups,
respectively.
The evaluation of AEs by anticholinergic use
showed that for the respective placebo,
onabotulinumtoxinA 200U, and 300U groups,
incidences of UTI were 43.1%, 58.7%, and
57.4% in users and 26.5%, 43.8%, and 54.5%
in non-users, and respective incidences of
urinary retention were 2.9%, 14.9%, and
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DISCUSSION
These pooled data from two phase 3 trials
include the largest cohorts of MS and SCI
patients with UI due to NDO studied to date.
Treatment with onabotulinumtoxinA resulted
in significant improvements in UI, urodynamic
parameters, and QOL in these patients
regardless of etiology. Consistent with
previous analyses [6, 7], there was no
advantage in terms of efficacy for the 300U
dose of onabotulinumtoxinA compared with
the 200U dose in either the SCI or MS
subpopulations. The only notable differences
in efficacy between etiologies were that a larger
placebo response was seen in change from
baseline in UI episodes in the MS population,
and a greater magnitude of reduction in
PdetmaxIDC was observed in the SCI population.
This larger placebo response in the MS
population may reflect that the majority of MS
patients were spontaneously voiding at
baseline, and the observed placebo response is
consistent with that of a non-neurogenic
population [9]. In addition, just under 20% of
the MS patients receiving placebo initiated CIC
during the study. Many of these patients would
likely have benefited from CIC prior to study
entry, and the improved bladder emptying with
CIC alone may have contributed to the
improvements seen in MS patients receiving
placebo. Nevertheless, the treatment effect
Fig. 4 Proportion (%) of MS patients in the 200U dose group with duration of de novo CIC use for urinary retention.
*1/7 patients and 11/14 patients had CIC ongoing at exit. CIC clean intermittent catheterization, MS multiple sclerosis
Fig. 5 Satisfaction proﬁle at week 6 in MS patients who were not using CIC at baseline and a initiated CIC post treatment
or b remained off CIC. CIC clean intermittent catheterization, MS multiple sclerosis, OnabotA onabotulinumtoxinA
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between onabotulinumtoxinA and placebo in
MS and SCI patients was similar. The greater
reduction in PdetmaxIDC observed in the SCI
group is likely a reflection of the higher baseline
values in the SCI population.
Patients of both etiologies exhibited
improvements in I-QOL total scores that were
considerably greater than the established MID
of 11 points [8], with the magnitude of change
being greatest in the MS population. This
implies that these neurogenic populations
have an improved health-related QOL when
treated with onabotulinumtoxinA.
OnabotulinumtoxinA was well tolerated in
both the MS and SCI populations, with the
voiding pattern prior to treatment being the key
difference between the two etiologies. The
majority of MS patients were not using CIC
prior to treatment, whereas the majority of SCI
patients were. Therefore, the occurrence of
urinary retention, initiation of CIC, and UTI
rates were higher post treatment in the MS
population. Nevertheless, in those MS patients
not using CIC at baseline, the majority
continued to avoid the need to use CIC for
urinary retention post treatment (59/86
[68.6%]) or catheterized for urinary retention
for a duration of B18 weeks (10/86 [11.6%]). In
those who initiated CIC, the mean frequency
was about 2.5 times/day, indicating that many
maintained some ability to spontaneously void.
MS patients’ satisfaction with treatment
appeared to be independent of initiation of
CIC, in line with previous findings that patient
QOL is not affected by initiation of CIC after
treatment with onabotulinumtoxinA [10, 11].
Furthermore, the higher incidence of UTI did
not result in higher rates of complicated UTI.
In addition to examining the data by etiology,
pooling the data provided a large sample size to
examine onabotulinumtoxinA treatment with
and without concomitant anticholinergic use.
Fig. 6 UI by anticholinergic use in the pooled ITT
population. a Mean change from baseline in weekly UI
episodes. b Responder rates for C50% and 100% reductions
in UI episodes at week 6. *P\0.001; P\0.05;
P\0.005 vs placebo. AC anticholinergic, ITT intent-
to-treat, OnabotA onabotulinumtoxinA, UI urinary
incontinence
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Though widely used as first-line treatment for
NDO, anticholinergics are not always effective or
may have intolerable side effects, and many
patients discontinue their use [12, 13]. This
study found that improvements in UI,
urodynamics, QOL, and duration of effect
were independent of anticholinergic use. One
possible explanation for the lack of an additional
effect of anticholinergics in the presence
of onabotulinumtoxinA may be that
onabotulinumtoxinA, by directly blocking the
release of acetylcholine into the neuromuscular
junction [14], may provide a more efficacious
method for preventing muscarinic receptor
activation than antimuscarinic drugs, which act
by competitive blockade of the receptors [12].
A systematic review that examined studies
in which patients were treated concomitantly
with onabotulinumtoxinA and anticholinergics
found that 28–58% of patients treated
with onabotulinumtoxinA discontinued
anticholinergics and most reduced their dose
[15]. However, the pooled studies presented
here were not designed to examine the effects of
dose decreases or discontinuation of
anticholinergics with onabotulinumtoxinA
treatment. Rather, the protocols of these
pivotal efficacy/safety trials required that
anticholinergic doses remained constant
during the study so as not to confound the
results, and the trials in our analysis only
included NDO patients who were inadequately
managed by anticholinergics.
CONCLUSION
OnabotulinumtoxinA significantly improved UI
episodes per week, urodynamic parameters, and
QOL in both SCI and MS patients with UI due
to NDO and regardless of concurrent
anticholinergic use. OnabotulinumtoxinA was
well tolerated in all subgroups.
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